✦ For You Geopolitics Tech Finance Health Energy Sports Culture ◆ SN Last Week ★ Saved

The Organization file

FDA

30 stories · 5 sources · updated every week

The FDA faces scrutiny over its peptide policy, now with the White House, while ex-chiefs warn of a 3,500-position deficit impacting drug reviews. Watch for the mifepristone safety review's March 2027 completion and potential stem cell roundtables by year-end.

Timeline

The Carcinogen That Stopped Ship Fires—Now in Your Seafood

HHS advances peptide plan; China curbs biotech exports

FDA Submits Peptide Policy to White House

HHS sends peptide plan to White House for review

Auchincloss: Boost U.S. Biotech, Don't Target China

Ex-FDA Chiefs Slam DOGE Cuts as 'Disaster'

Compass CEO pledges 'go slow' psychedelic drug launch

Three Ex-FDA Chiefs Call DOGE 'Biggest Disaster'

Intero Sends Mini Human Intestines to Drugmakers

Whoop Joins Medicare ACCESS Program; Must Prove Outcomes

States can build public vaccine factories as VICP backup

40% of FDA panel meetings had pharma-linked patient reps

STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug

Efferon NEO gets first pediatric sepsis CE mark

FDA Approves First Drug to Treat Narcolepsy Itself

The Guardian Science

Cochrane Review: Vapes Beat Patches, Gum to Quit

FDA says its safety review of abortion pill will continue into next year

Lacosamide reverses cartilage damage in Yale study

Caribou Biosciences Shuts Down After Failing to Fund Trial

STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few

Shows up with